Idera Pharmaceuticals, Inc. (IDRA) financial statements (2022 and earlier)

Company profile

Business Address 505 EAGLEVIEW BOULEVARD
EXTON, PA 19341
State of Incorp. DE
Fiscal Year End December 31
SIC 2836 - Biological Products, Except Diagnostic Substances (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in thousands)

12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments, including:32,50037,70042,80071,431112,629109,01460,160
Cash and cash equivalents32,54533,22940,01971,431112,62980,66726,586
Short-term investments 4,4992,774  28,34733,574
Other undisclosed cash, cash equivalents, and short-term investments(45)(28)7    
Other undisclosed current assets1,5383,6553,4681,3763,9922,0303,082
Total current assets:34,03841,35546,26872,807116,621111,04463,242
Noncurrent Assets
Operating lease, right-of-use asset7349301,054
Property, plant and equipment2244972071,4721,8531,692
Long-term investments and receivables      26,997
Long-term investments      26,997
Regulated entity, other noncurrent assets     717
Restricted cash and investments    300300311
Other undisclosed noncurrent assets7070709242717
Total noncurrent assets:8261,0441,2212161,7962,18729,034
TOTAL ASSETS:34,86442,39947,48973,023118,417113,23192,276
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities4,6536,4017,9189,0189,3347,9505,443
Accounts payable5653294571,1341,3345561,169
Accrued liabilities4,0886,0727,4617,8848,0007,3944,274
Debt  163 209292261
Derivative instruments and hedges, liabilities  46,436    
Deferred revenue and credits5661,1111,111
Other liabilities 435     
Other undisclosed current liabilities209191     
Total current liabilities:4,8627,02754,5179,01810,1099,3536,815
Noncurrent Liabilities
Long-term debt and lease obligation549758899  209501
Long-term debt, excluding current maturities     209501
Operating lease, liability549758899
Liabilities, other than long-term debt 118,803 116133201,378
Deferred revenue and credits 1521,262
Other liabilities   11613168116
Derivative instruments and hedges, liabilities 118,803     
Other undisclosed noncurrent liabilities(549)6,9833,241    
Total noncurrent liabilities:549126,5444,140116135291,879
Total liabilities:5,411133,57158,6579,02910,7229,8828,694
Stockholders' equity
Stockholders' equity attributable to parent29,453(91,172)(11,168)63,994107,695103,34983,582
Common stock53383027196149121
Additional paid in capital764,861742,342709,692728,342711,993641,687583,676
Accumulated other comprehensive loss     (17)(134)
Accumulated deficit(735,461)(833,552)(720,890)(664,375)(604,494)(538,470)(500,081)
Total stockholders' equity:29,453(91,172)(11,168)63,994107,695103,34983,582
TOTAL LIABILITIES AND EQUITY:34,86442,39947,48973,023118,417113,23192,276

Income statement (P&L) ($ in thousands)

12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
Revenues  1,44866290216,199249
Revenue, net90216,199249
Gross profit:  1,44866290216,199249
Operating expenses(27,673)(36,687)(47,515)(61,618)(67,369)(54,956)(49,095)
Operating loss:(27,673)(36,687)(46,067)(60,956)(66,467)(38,757)(48,846)
Nonoperating income (expense)(15)1371,1141,086533448396
Investment income, nonoperating91651,1501,089574415357
Foreign currency transaction gain (loss), before tax(24)(28)(36)(3)(41)3339
Interest and debt expense(7)(3) (11)(50)(80) 
Loss before gain (loss) on sale of properties:(27,695)(36,553)(44,953)(59,881)(65,984)(38,389)(48,450)
Other undisclosed net income (loss)125,786(76,109)(11,562)    
Net income (loss):98,091(112,662)(56,515)(59,881)(65,984)(38,389)(48,450)
Other undisclosed net loss attributable to parent      (105)
Net income (loss) attributable to parent:98,091(112,662)(56,515)(59,881)(65,984)(38,389)(48,555)
Preferred stock dividends and other adjustments  (28,043)    
Undistributed earnings (loss) allocated to participating securities, basic(1,150)    
Net income (loss) available to common stockholders, basic:96,941(112,662)(84,558)(59,881)(65,984)(38,389)(48,555)
Dilutive securities, effect on basic earnings per share(118,803)      
Other undisclosed net loss available to common stockholders, diluted(6,983)      
Net loss available to common stockholders, diluted:(28,845)(112,662)(84,558)(59,881)(65,984)(38,389)(48,555)

Comprehensive Income ($ in thousands)

12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
Net income (loss):98,091(112,662)(56,515)(59,881)(65,984)(38,389)(48,450)
Comprehensive income (loss):98,091(112,662)(56,515)(59,881)(65,984)(38,389)(48,450)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent    17117(222)
Comprehensive income (loss), net of tax, attributable to parent:98,091(112,662)(56,515)(59,881)(65,967)(38,272)(48,672)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: